


The Claim Amendments

Please amend the claims as follows:

1. (Currently amended) A compound of the formula:



or a pharmaceutically acceptable salt thereof; wherein

Y is selected from $-(\text{CH}_2)-Q_1$; $-(\text{CO})-Q_1$; $-(\text{CO})\text{NH}-Q_1$; $-(\text{CO})-\text{O}-Q_1$; $-(\text{SO}_2)-Q_1$ or $-(\text{SO}_2)\text{NH}-Q_1$;

Q_1 is a C_1-C_6 straight chain or branched alkyl or alkenyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system, wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from NH_2 , $\text{NH}-R$, $\text{N}(R)_2$, NO_2 , OH , OR , CF_3 , halo, CN , CO_2H , $\text{C}(\text{O})-\text{NH}_2$, $\text{C}(\text{O})-\text{NH}-R$, $\text{C}(\text{O})-\text{N}(R)_2$, $\text{C}(\text{O})-R$, SR , $S(O)-R$, $S(O)_2-R$, $S(O)_2-\text{NH}-R$ or $-R$;

R^1 is $-\text{NHR}^5$, $-\text{OR}^5$, $-\text{SR}^5$, or $-R^5$;

R^2 , R^3 , and R^4 are independently selected from $-(\text{CO})\text{NH}_2$, $-(\text{CO})\text{NHR}$, $-(\text{CO})\text{N}(R)_2$, $-\text{NHR}^5$, $-\text{NHCH}_2\text{R}^5$, $-\text{OR}^5$, $-\text{SR}^5$, $-R^5$, $-\text{NH}(\text{CO})-\text{R}^6$, $-\text{NH}(\text{CO})-\text{NHR}^6$, $-\text{NH}(\text{CO})-\text{NH}(\text{CO})\text{R}^6$, $-\text{NH}(\text{CO})-\text{OR}^6$, $-\text{NH}(\text{SO}_2)-\text{R}^6$, $-\text{NH}(\text{SO}_2)-\text{NHR}^6$, $-\text{C}(\text{O})\text{OH}$, $-\text{C}(\text{O})\text{OR}$, $-(\text{CO})-Q_1$, $-(\text{CO})\text{NH}-Q_1$, $-(\text{CO})\text{NR}-Q_1$, $-(\text{CO})-\text{O}-Q_1$, $-(\text{SO}_2)-Q_1$ or $-(\text{SO}_2)\text{NH}-Q_1$;

R^5 and R^6 are each independently selected from H; $\text{N}(R)_2$, NHOH , NO_2 , $\text{C}(\text{O})\text{OR}$ or halo; a C_1-C_6 straight chain or branched alkyl, alkenyl or alkynyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14

membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, NHC(O)OR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, Si(R)₃, CO₂H, COOR, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R;

R is a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

provided that:

~~when R₁, R₂, R₃, and R₄ are H, then Y is not 2,2-diethoxyethyl, 2-chloroethyl, 4-chlorobutyl, ethyl, 2-hydroxyethyl, methyl, isopropyl, or unsubstituted benzyl; when R₁, R₂, and R₄ are H, and R₃ is Br, then Y is not unsubstituted benzyl, ethyl, or methyl; when R₁ and R₃ are CH₃, and R₂ and R₄ are H, then Y is not ethyl; when R₁ and R₃ are H, and R₂ and R₄ are Cl, then Y is not ethyl; and when R₁, R₂ and R₄ are H, and R₃ is CH₃, then Y is not ethyl.~~

2-15. Canceled.

16. (Previously presented) The compound of claim 1, wherein Y is -(CH₂)₂-Q₁ and Q₁ is optionally substituted benzodioxanyl.

17. (Previously presented) The compound of claim 1, wherein R¹ is R⁵.

18. (Previously presented) The compound of claim 1, wherein R¹ is H, methyl, halo, optionally substituted phenyl, a monocyclic or bicyclic heterocycle, optionally substituted alkyl, alkenyl or alkynyl, or COOR.

19. (Previously presented) The compound of claim 1, wherein R² is R⁵, NH(CO)-R⁶, NH(SO₂)-R⁶, -NHCH₂R⁵, CO-Q₁ or CONH-Q₁.

20. (Previously presented) The compound of claim 1, wherein R² is H, halo, NO₂, NH₂, methyl, OCF₃, -N(R)₂, or substituted phenyl.

21. (Previously presented) The compound of claim 1, wherein R³ is R⁵, NH(CO)-R⁶, NH(SO₂)-R⁶, or CONH-Q₁.


22. (Previously presented) The compound of claim 1, wherein R³ is H, halo, methyl, CF₃, optionally substituted phenyl, a heterocyclic ring, a bicyclic ring, NO₂ or NH₂.

23. (Previously presented) The compound of claim 1, wherein R⁴ is R⁵.


24. (Previously presented) The compound of claim 1, wherein R⁴ is H or methyl.

25-27. Canceled.


28. (New) The compound according to claim 1, wherein said compound is selected from the group depicted below:




64




65




69




70




71




75




76



77




81












85












86




90









135




138




141




148




149




152




153




154




156




159




160




161




163




165




167




168




169




170




172




173




174




175




177




178




179




181




182




183




184




186




187



188




190



191


192

193




195

196




201


202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226











227












228




229









247




248




249




250




251




252




253




254




255




256




257




258




259










260


















261




262









285




286




287




288



289












290




291

292







301




302




303




304




305




306




307




308




309




310




311




312




313




314




315




316




318




319




320




321




322




323




324




325




326




327




328




329




330




331




332




333




334




335




336




337




338




339










340




341




342







351




352



353



355




356

29. (New) A pharmaceutical composition comprising a compound according to either of claims 1 or 28 and a pharmaceutically acceptable carrier.

30. (New) A method for treating Parkinson's disease in a patient in need thereof, comprising administering the pharmaceutical composition of claim 29 to the patient.

31. (New) A compound of the formula:



or a pharmaceutically acceptable salt thereof; wherein

Y is -(CH₂)₋Q₁;

Q₁ is benzodioxanyl, a substituted phenyl group, a substituted 5-7 membered aromatic heterocyclic ring, a 10-membered heterocyclic bicyclic ring, or a straight chain alkyl group substituted with phenyl or a heterocyclic monocyclic or bicyclic ring, wherein said phenyl or heterocyclic ring is substituted with one to four substituents, each of which is independently selected from NH₂, NH-R, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, CO₂H, C(O)-NH₂, C(O)-NH-R, C(O)-N(R)₂, C(O)-R, SR, S(O)-R, S(O)₂-R, S(O)₂-NH-R or -R;

R¹ is R⁵;

R² is OCF₃, NH₂, R⁵, NH(CO)-R⁶, NH(SO₂)-R⁶, -NHCH₂R⁵, CO-Q₁ or CONH-Q₁;

R³ is NH(CO)-R⁶, NH(SO₂)-R⁶, CONH-Q₁, H, halo, methyl, CF₃, substituted or unsubstituted phenyl, a substituted or unsubstituted aromatic heterocyclic ring, an aromatic bicyclic ring, NO₂ or NH₂;

R⁴ is R⁵;

R⁵ and R⁶ are each independently selected from H; N(R)₂, NHOH, NO₂, C(O)OR or halo; a C₁-C₆ straight chain or branched

alkyl, alkenyl or alkynyl group; a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring; or a 9-14 membered bicyclic or tricyclic aromatic or non-aromatic carbocyclic or heterocyclic ring; wherein said alkyl, alkenyl, ring or ring system is optionally substituted with one to four substituents, each of which is independently selected from NH₂, NHR, NHC(O)OR, N(R)₂, NO₂, OH, OR, CF₃, halo, CN, Si(R)₃, CO₂H, COOR, CONH₂, CONHR, CON(R)₂, COR, SR, S(O)R, S(O)₂R, S(O)₂NHR or R; and

R is a C₁-C₆ straight chain or branched alkyl or alkenyl group, a 5-7 membered aromatic or non-aromatic carbocyclic or heterocyclic ring, or a 9-10 membered bicyclic aromatic or non-aromatic carbocyclic or heterocyclic ring system.

32. (New) The compound according to claim 31, wherein R¹ is H, methyl, halo, an optionally substituted phenyl, a monocyclic or bicyclic heterocycle, a substituted or unsubstituted alkyl, alkenyl or alkynyl, or COOR.


33. (New) The compound according to claim 31, wherein R² is H, halo, NO₂, NH₂, methyl, OCF₃, -N(R)₂, or substituted phenyl.

34. (New) The compound according to claim 31, wherein R³ is H, halo, methyl, CF₃, substituted or unsubstituted phenyl, an aromatic heterocyclic ring, a bicyclic ring, NO₂ or NH₂.


35. (New) The compound according to claim 31, wherein R⁴ is H or methyl.

36. (New) The compound according to claim 31, wherein Q₁ is a substituted phenyl group.


37. (New) The compound according to claim 36, wherein said compound is selected from the group depicted below:




1




2




3




4




5




6




7




8




9













10















11




12









38




39




40




41




42




43




44




46




47




48




49




50



51




52




54




55




56




57















58




59




60







82




83




84




87




88




89












92




93




94







121




131




134




137




140




143




145




147




150




151




162




164




166




171




176




180




185




198



199



200



354

38. (New) A pharmaceutical composition comprising a compound according to either of claims 31 or 37 and a pharmaceutically acceptable carrier.

39. (New) A method for treating Parkinson's disease in a patient in need thereof, comprising administering the pharmaceutical composition of claim 38 to the patient.